Skip to main content
. 2021 Jan 18;22(2):925. doi: 10.3390/ijms22020925

Table 1.

Patient and Disease Characteristics (No of patients: n = 43).

Parameters (n) (%)
Age (median; 67 years, range; 46–87)
Gender
Male 39 90.7
Female 4 9.3
Performance Status
0 22 51.16
1 14 32.56
2 7 16.28
Stage
IIIb 8 18.6
IV 35 81.4
Histological subtype
Squamous 14 32.6
Non-squamous 29 67.4
No of metastatic sites
<2 22 51.2
≥2 21 48.8
Metastatic sites
Lung 30 69.8
Bones 16 37.2
Liver 6 14
CNS 6 14
Adrenal gland 8 18.6
Lymph nodes 8 18.6
Peritoneum 1 2.3
Pancreas 1 2.3
EGFR status
wt 41 95.3
mutant 2 4.7
ALK status
wt 43 100
re-arranged 0 0
Smoking status
Non-smoker 6 14
Ex-smoker 12 27.9
Current 25 58.1
Chemotherapy type
Monotherapy 5 11.6
Doublet-chemotherapy 38 88.4
Best response to treatment
Partial response 16 37.2
Stable disease 12 27.9
Progressive disease 11 25.6
Non-evaluable 4 9.3

CNS: central nervous system; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; wt: wild type.